Professor Jan Vermorken discusses the impact of new data on the standard-of-care treatment for recurrent/metastatic head and neck cancer

The standard-of-care treatment for recurrent/metastatic head and neck cancer is cetuximab plus platinum-based therapy followed by cetuximab until progression (the EXTREME regime). Professor Jan Vermorken, a leading medical oncologist, discusses whether emerging immunotherapy agents, such as nivolumab, will have any impact on this treatment regime.